These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6199509)

  • 61. The main antigenic determinant detected by neutralizing monoclonal antibodies on the intact foot-and-mouth disease virus particle is absent from isolated VPI.
    Meloen RH; Briaire J; Woortmeyer RJ; van Zaane D
    J Gen Virol; 1983 May; 64(Pt 5):1193-8. PubMed ID: 6188800
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The antigenic relationship between measles, canine distemper and rinderpest viruses studied with monoclonal antibodies.
    Sheshberadaran H; Norrby E; McCullough KC; Carpenter WC; Orvell C
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1381-92. PubMed ID: 2425047
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
    Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
    Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2.
    Hastings GZ; Speller SA; Francis MJ
    J Gen Virol; 1990 Dec; 71 ( Pt 12)():3055-9. PubMed ID: 1703215
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Capsid destabilization is required for antibody-mediated disruption of poliovirus.
    Delaet I; Boeyé A
    J Gen Virol; 1994 Mar; 75 ( Pt 3)():581-7. PubMed ID: 8126454
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Strain differentiation of polioviruses with monoclonal antibodies.
    Osterhaus AD; van Wezel AL; Stegmann AJ; van Asten JA; Hazendonk AG
    Dev Biol Stand; 1984; 57():135-9. PubMed ID: 6098494
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Construction of a chimaeric type 1/type 2 poliovirus by genetic recombination.
    Martin A; Wychowski C; Benichou D; Crainic R; Girard M
    Ann Inst Pasteur Virol; 1988; 139(1):79-88. PubMed ID: 2849960
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epitope evolution in poliovirus maturation.
    Rombaut B; Vrijsen R; Boeyé A
    Arch Virol; 1983; 76(4):289-98. PubMed ID: 6194772
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
    Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
    J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction of neutralizing antibodies and immunity in vaccinated guinea pigs by cyanogen bromide-peptides of VP3 of foot-and-mouth disease virus.
    Kaaden OR; Adam KH; Strohmeier K
    J Gen Virol; 1977 Feb; 34(2):397-400. PubMed ID: 65445
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A study of the cellular immune response to enteroviruses in humans: identification of cross-reactive T cell epitopes on the structural proteins of enteroviruses.
    Cello J; Strannegård O; Svennerholm B
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2097-108. PubMed ID: 8811009
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Intertypic antigenic determinants of intracellular proteins of different poliovirus serotypes].
    Romanova LI; Tol'skaia EA; Agol VI
    Vopr Virusol; 1980; (5):570-3. PubMed ID: 6159736
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.
    Chow M; Yabrov R; Bittle J; Hogle J; Baltimore D
    Proc Natl Acad Sci U S A; 1985 Feb; 82(3):910-4. PubMed ID: 2983321
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1.
    Leclerc C; Deriaud E; Mimic V; van der Werf S
    J Virol; 1991 Feb; 65(2):711-8. PubMed ID: 1702841
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus.
    Ping LH; Jansen RW; Stapleton JT; Cohen JI; Lemon SM
    Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8281-5. PubMed ID: 2460866
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody.
    Uhlig J; Wiegers K; Dernick R
    Virology; 1990 Oct; 178(2):606-10. PubMed ID: 2171198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.